FibroGen Inc (FGEN) Stock
FGEN is no longer traded. FibroGen was delisted from the Nasdaq in January 2026.
Prices on this page are historical; the last trade was January 9, 2026 at $9.22.
FibroGen stock price history
FGEN final trading statistics
- Final close
- $9.22
- Final trading day
- Jan 9, 2026
- Market cap at delisting
- $37.30M
- Shares outstanding
- 4.05M
- Final 52-week range
- $0.23 – $12.60
- Avg. volume (final 3 mo.)
- 33,037
- All-time high (split-adj.)
- $1681.25 · Jul 2018
- All-time low (split-adj.)
- $5.16 · Jun 2025
- Return since IPO
- -98.3%
- Beta
- 0.77
- Book value / share
- -$4.21
- Price / book
- -2.19
FibroGen annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $29.62M | -$47.6M | -$0.56 |
| FY2023 | $46.80M | -$284.2M | -$2.80 |
| FY2022 | $140.73M | -$293.7M | -$3.14 |
| FY2021 | $235.31M | -$291.0M | -$3.14 |
| FY2020 | $176.32M | -$189.3M | -$2.13 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
FibroGen stock FAQ
What happened to FibroGen stock?
FibroGen stock was delisted from the Nasdaq. Its final close was $9.22 on January 9, 2026.
Is FGEN stock still trading?
No. FGEN was delisted from the Nasdaq in January 2026 and no longer trades on a U.S. exchange.
What was the last price of FGEN stock?
FGEN closed at $9.22 on its final trading day, January 9, 2026, for a market value of about $37.30M.
What were FibroGen's revenue and earnings in its last full fiscal year?
FibroGen reported revenue of $29.62M and net income of -$47.6M in fiscal 2024, its last full year as a public company.
When did FibroGen go public?
FibroGen Inc stock began trading on November 14, 2014.